Ksilink’s expertise lies in patient based, target free phenotypic drug discovery and preclinical development up to in vivo POC. Our ambition is to find new treatment solutions in the areas of muscular and cardiovascular diseases, neurodegenerative and psychiatric diseases. Ksilink further has launched several oncology and immune oncology projects.
Ksilink acts like a highly specialized open innovation center enabling technology transfer for academic and biotech partners.
December 15th, 2023